Accuray and RaySearch Agree to Collaboration Integrating RayStation Software with Accuray Platforms to Accelerate Accuray's Online Adaptive Capabilities
Accuray will invest $8 million in RayStation licenses as part of a joint push with RaySearch to commercialize online adaptive radiation therapy solutions.
Rhea-AI Summary
Accuray (ARAY) entered a definitive agreement with RaySearch Laboratories to expand their collaboration and accelerate Accuray's adoption of online adaptive radiation therapy.
The collaboration integrates Accuray's photon-based Radixact and, later, CyberKnife platforms and imaging with RaySearch's RayStation treatment planning and RayCare workflow software. Online adaptive radiation therapy enables adjustment of treatment plans immediately before delivery, based on the patient's current anatomy, with the goal of more personalized treatment and improved clinical efficiency. Under the agreement, Accuray will purchase specified RayStation licenses with a total order value of USD $8 million to support commercialization of these online adaptive solutions, which the companies will jointly market and support. RaySearch will further enhance its software to better support the Radixact platform and enable a more integrated workflow.
Positive
- USD $8 million RayStation license order underpins commercialization of online adaptive solutions
- Integration of RayStation and RayCare with Radixact and CyberKnife aims to enable online adaptive workflows
- Joint marketing and support structure may help accelerate clinical adoption of Accuray platforms
Negative
- Accuray commits to purchase $8 million in software licenses, increasing near-term cash outlays
Details
Market reaction after online adaptive partnership: ARAY +6.71%
Following this news, ARAY has gained 6.71%, reflecting a notable positive market reaction. Our momentum scanner has triggered 8 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $0.26. Trading volume is elevated at 2.6x the average, suggesting notable buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- License order value
- $8 million
- Specified RayStation licenses under the collaboration
Historical Context
-
Reported weaker fiscal-year revenue, lower product orders, and no formal fiscal 2027 guidance
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
online adaptive radiation therapy medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
The collaboration combines Accuray's advanced photon-based radiation therapy platforms and imaging capabilities with RaySearch's treatment planning and workflow software to enable online adaptive radiation therapy. The initial focus is on Accuray's Radixact® and the solution will be extended to the CyberKnife® platform in the future.
Online adaptive radiation therapy allows treatment plans to be adjusted immediately before treatment based on the patient's anatomy at the time of delivery. By bringing imaging, treatment planning and care coordination together, the solution is designed to support more personalized treatments while helping clinics work more efficiently.
Under the agreement, Accuray has agreed to purchase specified RayStation licenses (with a total order value of USD
"Advanced software is a key enabler of online adaptive radiation therapy. By combining RayStation and RayCare technology with Accuray's imaging and treatment delivery technologies, we are creating a comprehensive solution designed to simplify implementation and help more clinics adopt adaptive radiation therapy," says Johan Löf, founder and CEO of RaySearch. "Accuray's global presence, large installed base, differentiated technology, and worldwide service capabilities made them an ideal partner for us."
"Strategic partnerships are an important part of Accuray's growth strategy, enabling us to accelerate innovation while focusing on our core strengths. RaySearch's expertise in treatment planning, workflow software and system integration makes them a valuable partner as we advance our online adaptive radiation therapy strategy. By combining our complementary capabilities, we aim to bring efficient and personalized adaptive treatments to more patients worldwide," commented Steve LaNeve, CEO of Accuray.
About Accuray
Accuray is committed to expanding the potential of radiation therapy to improve as many lives as possible. The company develops unique, market-changing solutions designed to deliver radiation treatments for even the most complex cases, while making commonly treatable cases easier, helping to meet the full spectrum of patient needs. Accuray is dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery and beyond. Through collaboration with clinicians and administrators, the company aims to empower healthcare professionals to help patients return to their lives faster. Accuray is headquartered in
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected benefits of the collaboration and Accuray's future plans, performance, and growth opportunities. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including the risks described in Accuray's filings with the Securities and Exchange Commission, including its most recent Form 10-K and subsequent filings. Forward-looking statements speak only as of the date made, and Accuray undertakes no obligation to update them except as required by law.
Accuray Media Contact
Taylor Bould
Communications Specialist
tbould@accuray.com
About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure, and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems. RaySearch's software has been sold to over 1,200 clinics in 54 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003 (STO: RAY B). More information is available at raysearchlabs.com.
*Subject to regulatory clearance in some markets.
RaySearch Media Contact
Johan Löf, founder and CEO, RaySearch Laboratories AB
Tel: +46 (0) 8 510 530 00
Carolina Strömlid, Head of Investor Relations, RaySearch Laboratories AB
Tel: +46 (0) 708 807 173
ir@raysearchlabs.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-and-raysearch-agree-to-collaboration-integrating-raystation-software-with-accuray-platforms-to-accelerate-accurays-online-adaptive-capabilities-302876539.html
SOURCE Accuray Incorporated
FAQ
Which Accuray platforms are included in the collaboration with RaySearch?
The initial focus is on the Radixact platform. The companies state that the integrated online adaptive radiation therapy solution will be extended to the CyberKnife platform in the future.
What role does RayCare technology play in the collaboration?
RayCare technology will be used to simplify connectivity between clinical systems and support efficient online adaptive workflows, complementing RayStation treatment planning in the integrated solution.
How will the online adaptive solution be brought to market?
The agreement provides that the online adaptive radiation therapy solutions, supported by Accuray's purchase of RayStation licenses, will be jointly marketed and supported by Accuray and RaySearch.